Biologics for psoriasis, grouped by class

Biologics are lab-made proteins, given by injection or IV infusion, that block one specific part of the immune system involved in psoriasis. That differs from an older pill like methotrexate or cyclosporine, which suppresses immune function more broadly. Dermatology groups biologics by the exact target they block. TNF-alpha inhibitors (etanercept/Enbrel, adalimumab/Humira, infliximab/Remicade, certolizumab pegol/Cimzia, golimumab/Simponi) block tumor necrosis factor-alpha. The IL-12/23 inhibitor ustekinumab (Stelara) blocks a subunit shared by two different inflammatory signals. IL-23 inhibitors (guselkumab/Tremfya, risankizumab/Skyrizi, tildrakizumab/Ilumya) block only the newer, more specific IL-23 pathway. IL-17 inhibitors (secukinumab/Cosentyx, ixekizumab/Taltz, bimekizumab/Bimzelx, and brodalumab/Siliq) act further downstream in the same inflammatory cascade. Brodalumab is the exception: it blocks the IL-17 receptor itself rather than the cytokine. All of them lower the same underlying immune overactivity. They differ mainly in which exact protein they interrupt, and that difference changes dosing, side-effect pattern, and response speed.⌁ Evidence⌁ Evidence

Biologics are generally used for moderate-to-severe plaque psoriasis that has not responded well enough to topical treatment, phototherapy, or oral systemic medicines. Several are separately approved for psoriatic arthritis. Before starting any biologic, standard practice is a tuberculosis skin or blood test and often a hepatitis B blood test, since these medicines can reactivate a latent infection. Live vaccines are avoided during treatment, and starting is generally delayed if you have an active infection. These are class-wide precautions, not specific to any one drug.⌁ Evidence⌁ Evidence

Most biologics are given by subcutaneous injection, and dosing frequency varies widely by class and drug, from twice a week down to once every three months. Many people learn to give the injection themselves at home. Infliximab is the one exception on this list, requiring an IV infusion at a doctor’s office or infusion center rather than a self-administered shot. In clinical trials, response is usually measured by PASI, the standard psoriasis-severity score, at week 12 to 16. Reported response rates differ by class and by which PASI threshold is measured. TNF-class trials report roughly 49% to 80% reaching PASI 75 (75% clearing). The IL-12/23 drug ustekinumab reports roughly 66% to 75% PASI 75. IL-17 drugs report roughly 77% to 91% reaching the higher PASI 90 bar, and IL-23 drugs report roughly 70% to 75% PASI 90. These figures come from different trials of different drugs, not one head-to-head study. Mixing a PASI 75 figure against a PASI 90 figure is not an apples-to-apples comparison.⌁ Evidence⌁ Evidence

People I have heard from ask about the infection risk before they ask how well a biologic clears skin. Every biologic listed here can raise the risk of infection, because each one calms down a piece of the immune system on purpose. Report a fever, cough, flu-like symptoms, or any other infection sign to your dermatologist right away. TNF-class biologics carry a specific FDA boxed warning. MedlinePlus’s summary of the adalimumab (Humira) label states that using it may decrease your ability to fight infection and increase the chance of a serious infection. That same label states some children, teenagers, and young adults who received adalimumab or a similar medicine developed severe or life-threatening cancers. It also states adults face an increased risk of skin cancer, lymphoma, and other cancers. Two IL-17-class drugs carry their own distinct warning. Brodalumab’s label carries a boxed warning for suicidal ideation and behavior that calls for regular evaluation of suicide risk. Bimekizumab’s current label carries a similar warning and precaution. Common, non-boxed side effects reported across the group include upper respiratory infection, injection-site reactions, flu-like symptoms, urinary tract infection, and headache.⌁ Evidence⌁ Evidence⌁ Evidence

A JAMA Dermatology modeling study compared biologic therapy with phototherapy in a simulated population of adults with moderate-to-severe plaque psoriasis. It found a mean yearly out-of-pocket cost of about $2,000 for biologics, against a mean total yearly cost (patient plus payer combined) of about $84,034. Every biologic named here has its own list price, insurance-coverage rules, and often its own manufacturer copay card or patient-assistance program. No single number applies to one drug or to your plan. The National Psoriasis Foundation offers a free Patient Navigator service, described as giving “personalized help getting the treatment you need.” It can help work through cost and access questions for a specific biologic.⌁ Evidence⌁ Evidence

No reader has sent me a first-hand account of a specific biologic yet, and I have no documented pattern for any one drug or class. I will not generalize across twelve very different medicines to fill that gap. Until someone writes, here is what the labels and the studies say about living with one.⌁ Evidence

Track any sign of infection: fever, unusual fatigue, a cough, a wound that will not heal. Report it promptly, since every biologic named here carries that risk. If you are on brodalumab or bimekizumab, also track your mood. Tell your dermatologist about any new or worsening depression or thoughts of self-harm right away; their labels call for regular evaluation of that specific risk. Note any injection-site reaction (redness, swelling, itching where you inject) and how long it lasts. Add a same-conditions photo around the twelve-to-sixteen-week mark, matching the trial timeline the response-rate ranges above describe. That gives you and your dermatologist something concrete to compare against your own starting point.⌁ Evidence⌁ Evidence